motherlodetv.net
World Class Extractions Inc. (the “Company” or “World Class”) (CSE: PUMP) is pleased to announce that, effective immediately, it has appointed Anthony Durkacz as Chair of the Board of Directors. Mr. Durkacz was recently appointed to the Company’s Board of Directors in conjunction with its recent merger with Quadron Cannatech Corporation.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today that its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”) has received its Full Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license is effective as of June 21, 2019.
In accordance with the requirements of National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (“NI 62-103“), World Class Extractions Inc. (the “Reporter“) announces that it has acquired beneficial ownership and control over 71,650,447 common shares (“Common Shares“) in the capital of Quadron Cannatech Corporation (“Quadron“), which represents 100% of the issued and outstanding Common Shares.
World Class Extractions Inc. (“World Class”) (CSE: PUMP) and Quadron Cannatech Corporation (“Quadron”) (CSE: QCC) are pleased to announce that that they have completed their previously announced plan of arrangement (the “Arrangement”) under the provisions of the Business Corporations Act (British Columbia), pursuant to which World Class has acquired all of the common shares of Quadron (the “Quadron Shares”) following Quadron’s amalgamation with World Class’s wholly-owned subsidiary, 1212476 B.C. LTD., to form a new wholly-owned subsidiary of World Class continuing as “Quadron Cannatech Corporation” (“Amalco”).
World Class Extractions Inc. (CSE: PUMP) (“World Class“) and Quadron Cannatech Corporation (“Quadron“) (CSE: QCC) are pleased to announce that, at the special meeting of the shareholders of Quadron held on June 7, 2019 (the “Meeting“), the shareholders of Quadron voted in favour of a special resolution to approve the proposed transaction, pursuant to which, among other things, World Class will acquire all of the issued and outstanding shares of Quadron, by way of a court-approved plan of arrangement (the “Arrangement“) as previously announced on April 16, 2019.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), is pleased to announce the addition of two distinguished cannabis researchers to the company’s Scientific Advisory Board (“SAB”).
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), announced today that Executive Co-Chairman and Chief Executive Officer, Dr. Raza Bokhari, will be featured in the 2019 BIO International Convention’s panel presentation, “Building a Winning Team for Biotech Business Success – Lessons You Can Learn from Industry Veterans and Former NFL Player Turned Broadcaster Solomon Wilcots,” on June 4 in Philadelphia, PA.
The Board of Directors of FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), unanimously voted Raza Bokhari, M.D., Executive Co-Chairman of the Board, as permanent Chief Executive Officer. Dr. Bokhari has served as interim CEO of the Company since February.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”) would like to congratulate High Tide Inc. (CSE: HITI) (OTCQB: HITIF) (FRA: 2LY) (“High Tide”) on the recent announcement from Alberta Gaming, Liquor and Cannabis lifting the moratorium on issuing cannabis licenses and accepting license applications. The announcement is an encouraging sign of steadily improving cannabis supply levels in Alberta and is a positive step for companies like High Tide that have numerous stores ready and waiting to retail cannabis products.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”), today announced the appointment of pharmaceutical industry leader, Edward J. Brennan, Jr., M.D., FACS, as President of its biosciences division. Dr. Brennan has more than 25 years’ experience in leadership roles at major pharmaceutical companies and clinical research organizations.